世界のノイラミニダーゼ阻害薬市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Neuraminidase Inhibitors Drug Market Size, Status and Forecast 2021-2027

• レポートコード：QFJ1-5878
• 出版社/出版日：QYResearch / 2021年6月
※2024年版があります。お問い合わせください。
• レポート形態：英文、PDF、86ページ
• 納品方法：Eメール（納期：3日）
• 産業分類：医薬品

• 販売価格（消費税別）

Single User	￥577,200 (USD3,900)	▷ お問い合わせ
Multi User	￥865,800 (USD5,850)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

レポート概要

QYResearch社発行の本調査レポートでは、ノイラミニダーゼ阻害薬の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（オセルタミビル、ザナミビル、ペラミビル、ラニナミビル）、用途別市場規模（病院薬局、小売薬局、オンライン薬局、その他）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、企業情報などをまとめております。
・市場概要
・ノイラミニダーゼ阻害薬の市場動向
・企業の競争状況、市場シェア
・ノイラミニダーゼ阻害薬の種類別市場規模と予測2016-2027（オセルタミビル、ザナミビル、ペラミビル、ラニナミビル）
・ノイラミニダーゼ阻害薬の用途別市場規模と予測2016-2027（病院薬局、小売薬局、オンライン薬局、その他）
・ノイラミニダーゼ阻害薬の北米市場規模2016-2027（アメリカ、カナダ）
・ノイラミニダーゼ阻害薬の欧州市場規模2016-2027（ドイツ、フランス、イギリス等）
・ノイラミニダーゼ阻害薬のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等）
・ノイラミニダーゼ阻害薬の中南米市場規模2016-2027（メキシコ、ブラジル）
・ノイラミニダーゼ阻害薬の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等）
・主要企業情報（Roche、GSK、Gilead Sciences、Daiichi Sankyo）
・結論

Neuraminidase Inhibitors (NAIs) are the type of drugs that are used to block the neuraminidase enzyme.

Market Analysis and Insights: Global Neuraminidase Inhibitors Drug Market
The global Neuraminidase Inhibitors Drug market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Neuraminidase Inhibitors Drug market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Neuraminidase Inhibitors Drug market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Neuraminidase Inhibitors Drug market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Neuraminidase Inhibitors Drug market.

Global Neuraminidase Inhibitors Drug Scope and Market Size
Neuraminidase Inhibitors Drug market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Neuraminidase Inhibitors Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Oseltamivir
Zanamivir
Peramivir
Laninamivir

Segment by Application
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Others

By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Roche
GSK
Gilead Sciences
Daiichi Sankyo

レポート目次

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Neuraminidase Inhibitors Drug Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Oseltamivir
1.2.3 Zanamivir
1.2.4 Peramivir
1.2.5 Laninamivir
1.3 Market by Application
1.3.1 Global Neuraminidase Inhibitors Drug Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospital Pharmacy
1.3.3 Retail Pharmacy
1.3.4 Online Pharmacy
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Neuraminidase Inhibitors Drug Market Perspective (2016-2027)
2.2 Neuraminidase Inhibitors Drug Growth Trends by Regions
2.2.1 Neuraminidase Inhibitors Drug Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Neuraminidase Inhibitors Drug Historic Market Share by Regions (2016-2021)
2.2.3 Neuraminidase Inhibitors Drug Forecasted Market Size by Regions (2022-2027)
2.3 Neuraminidase Inhibitors Drug Industry Dynamic
2.3.1 Neuraminidase Inhibitors Drug Market Trends
2.3.2 Neuraminidase Inhibitors Drug Market Drivers
2.3.3 Neuraminidase Inhibitors Drug Market Challenges
2.3.4 Neuraminidase Inhibitors Drug Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Neuraminidase Inhibitors Drug Players by Revenue
3.1.1 Global Top Neuraminidase Inhibitors Drug Players by Revenue (2016-2021)
3.1.2 Global Neuraminidase Inhibitors Drug Revenue Market Share by Players (2016-2021)
3.2 Global Neuraminidase Inhibitors Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Neuraminidase Inhibitors Drug Revenue
3.4 Global Neuraminidase Inhibitors Drug Market Concentration Ratio
3.4.1 Global Neuraminidase Inhibitors Drug Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Neuraminidase Inhibitors Drug Revenue in 2020
3.5 Neuraminidase Inhibitors Drug Key Players Head office and Area Served
3.6 Key Players Neuraminidase Inhibitors Drug Product Solution and Service
3.7 Date of Enter into Neuraminidase Inhibitors Drug Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Neuraminidase Inhibitors Drug Breakdown Data by Type
4.1 Global Neuraminidase Inhibitors Drug Historic Market Size by Type (2016-2021)
4.2 Global Neuraminidase Inhibitors Drug Forecasted Market Size by Type (2022-2027)

5 Neuraminidase Inhibitors Drug Breakdown Data by Application
5.1 Global Neuraminidase Inhibitors Drug Historic Market Size by Application (2016-2021)
5.2 Global Neuraminidase Inhibitors Drug Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Neuraminidase Inhibitors Drug Market Size (2016-2027)
6.2 North America Neuraminidase Inhibitors Drug Market Size by Type
6.2.1 North America Neuraminidase Inhibitors Drug Market Size by Type (2016-2021)
6.2.2 North America Neuraminidase Inhibitors Drug Market Size by Type (2022-2027)
6.2.3 North America Neuraminidase Inhibitors Drug Market Size by Type (2016-2027)
6.3 North America Neuraminidase Inhibitors Drug Market Size by Application
6.3.1 North America Neuraminidase Inhibitors Drug Market Size by Application (2016-2021)
6.3.2 North America Neuraminidase Inhibitors Drug Market Size by Application (2022-2027)
6.3.3 North America Neuraminidase Inhibitors Drug Market Size by Application (2016-2027)
6.4 North America Neuraminidase Inhibitors Drug Market Size by Country
6.4.1 North America Neuraminidase Inhibitors Drug Market Size by Country (2016-2021)
6.4.2 North America Neuraminidase Inhibitors Drug Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada

7 Europe
7.1 Europe Neuraminidase Inhibitors Drug Market Size (2016-2027)
7.2 Europe Neuraminidase Inhibitors Drug Market Size by Type
7.2.1 Europe Neuraminidase Inhibitors Drug Market Size by Type (2016-2021)
7.2.2 Europe Neuraminidase Inhibitors Drug Market Size by Type (2022-2027)
7.2.3 Europe Neuraminidase Inhibitors Drug Market Size by Type (2016-2027)
7.3 Europe Neuraminidase Inhibitors Drug Market Size by Application
7.3.1 Europe Neuraminidase Inhibitors Drug Market Size by Application (2016-2021)
7.3.2 Europe Neuraminidase Inhibitors Drug Market Size by Application (2022-2027)
7.3.3 Europe Neuraminidase Inhibitors Drug Market Size by Application (2016-2027)
7.4 Europe Neuraminidase Inhibitors Drug Market Size by Country
7.4.1 Europe Neuraminidase Inhibitors Drug Market Size by Country (2016-2021)
7.4.2 Europe Neuraminidase Inhibitors Drug Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Neuraminidase Inhibitors Drug Market Size (2016-2027)
8.2 Asia-Pacific Neuraminidase Inhibitors Drug Market Size by Type
8.2.1 Asia-Pacific Neuraminidase Inhibitors Drug Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Neuraminidase Inhibitors Drug Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Neuraminidase Inhibitors Drug Market Size by Type (2016-2027)
8.3 Asia-Pacific Neuraminidase Inhibitors Drug Market Size by Application
8.3.1 Asia-Pacific Neuraminidase Inhibitors Drug Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Neuraminidase Inhibitors Drug Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Neuraminidase Inhibitors Drug Market Size by Application (2016-2027)
8.4 Asia-Pacific Neuraminidase Inhibitors Drug Market Size by Region
8.4.1 Asia-Pacific Neuraminidase Inhibitors Drug Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Neuraminidase Inhibitors Drug Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Neuraminidase Inhibitors Drug Market Size (2016-2027)
9.2 Latin America Neuraminidase Inhibitors Drug Market Size by Type
9.2.1 Latin America Neuraminidase Inhibitors Drug Market Size by Type (2016-2021)
9.2.2 Latin America Neuraminidase Inhibitors Drug Market Size by Type (2022-2027)
9.2.3 Latin America Neuraminidase Inhibitors Drug Market Size by Type (2016-2027)
9.3 Latin America Neuraminidase Inhibitors Drug Market Size by Application
9.3.1 Latin America Neuraminidase Inhibitors Drug Market Size by Application (2016-2021)
9.3.2 Latin America Neuraminidase Inhibitors Drug Market Size by Application (2022-2027)
9.3.3 Latin America Neuraminidase Inhibitors Drug Market Size by Application (2016-2027)
9.4 Latin America Neuraminidase Inhibitors Drug Market Size by Country
9.4.1 Latin America Neuraminidase Inhibitors Drug Market Size by Country (2016-2021)
9.4.2 Latin America Neuraminidase Inhibitors Drug Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Neuraminidase Inhibitors Drug Market Size (2016-2027)
10.2 Middle East & Africa Neuraminidase Inhibitors Drug Market Size by Type
10.2.1 Middle East & Africa Neuraminidase Inhibitors Drug Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Neuraminidase Inhibitors Drug Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Neuraminidase Inhibitors Drug Market Size by Type (2016-2027)
10.3 Middle East & Africa Neuraminidase Inhibitors Drug Market Size by Application
10.3.1 Middle East & Africa Neuraminidase Inhibitors Drug Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Neuraminidase Inhibitors Drug Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Neuraminidase Inhibitors Drug Market Size by Application (2016-2027)
10.4 Middle East & Africa Neuraminidase Inhibitors Drug Market Size by Country
10.4.1 Middle East & Africa Neuraminidase Inhibitors Drug Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Neuraminidase Inhibitors Drug Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Roche
11.1.1 Roche Company Details
11.1.2 Roche Business Overview
11.1.3 Roche Neuraminidase Inhibitors Drug Introduction
11.1.4 Roche Revenue in Neuraminidase Inhibitors Drug Business (2016-2021)
11.1.5 Roche Recent Development
11.2 GSK
11.2.1 GSK Company Details
11.2.2 GSK Business Overview
11.2.3 GSK Neuraminidase Inhibitors Drug Introduction
11.2.4 GSK Revenue in Neuraminidase Inhibitors Drug Business (2016-2021)
11.2.5 GSK Recent Development
11.3 Gilead Sciences
11.3.1 Gilead Sciences Company Details
11.3.2 Gilead Sciences Business Overview
11.3.3 Gilead Sciences Neuraminidase Inhibitors Drug Introduction
11.3.4 Gilead Sciences Revenue in Neuraminidase Inhibitors Drug Business (2016-2021)
11.3.5 Gilead Sciences Recent Development
11.4 Daiichi Sankyo
11.4.1 Daiichi Sankyo Company Details
11.4.2 Daiichi Sankyo Business Overview
11.4.3 Daiichi Sankyo Neuraminidase Inhibitors Drug Introduction
11.4.4 Daiichi Sankyo Revenue in Neuraminidase Inhibitors Drug Business (2016-2021)
11.4.5 Daiichi Sankyo Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Neuraminidase Inhibitors Drug Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Oseltamivir
Table 3. Key Players of Zanamivir
Table 4. Key Players of Peramivir
Table 5. Key Players of Laninamivir
Table 6. Global Neuraminidase Inhibitors Drug Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global Neuraminidase Inhibitors Drug Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 8. Global Neuraminidase Inhibitors Drug Market Size by Regions (2016-2021) & (US$ Million)
Table 9. Global Neuraminidase Inhibitors Drug Market Share by Regions (2016-2021)
Table 10. Global Neuraminidase Inhibitors Drug Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 11. Global Neuraminidase Inhibitors Drug Market Share by Regions (2022-2027)
Table 12. Neuraminidase Inhibitors Drug Market Trends
Table 13. Neuraminidase Inhibitors Drug Market Drivers
Table 14. Neuraminidase Inhibitors Drug Market Challenges
Table 15. Neuraminidase Inhibitors Drug Market Restraints
Table 16. Global Neuraminidase Inhibitors Drug Revenue by Players (2016-2021) & (US$ Million)
Table 17. Global Neuraminidase Inhibitors Drug Market Share by Players (2016-2021)
Table 18. Global Top Neuraminidase Inhibitors Drug Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Neuraminidase Inhibitors Drug as of 2020)
Table 19. Ranking of Global Top Neuraminidase Inhibitors Drug Companies by Revenue (US$ Million) in 2020
Table 20. Global 5 Largest Players Market Share by Neuraminidase Inhibitors Drug Revenue (CR5 and HHI) & (2016-2021)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Neuraminidase Inhibitors Drug Product Solution and Service
Table 23. Date of Enter into Neuraminidase Inhibitors Drug Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Neuraminidase Inhibitors Drug Market Size by Type (2016-2021) (US$ Million)
Table 26. Global Neuraminidase Inhibitors Drug Revenue Market Share by Type (2016-2021)
Table 27. Global Neuraminidase Inhibitors Drug Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 28. Global Neuraminidase Inhibitors Drug Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 29. Global Neuraminidase Inhibitors Drug Market Size Share by Application (2016-2021) & (US$ Million)
Table 30. Global Neuraminidase Inhibitors Drug Revenue Market Share by Application (2016-2021)
Table 31. Global Neuraminidase Inhibitors Drug Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 32. Global Neuraminidase Inhibitors Drug Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 33. North America Neuraminidase Inhibitors Drug Market Size by Type (2016-2021) (US$ Million)
Table 34. North America Neuraminidase Inhibitors Drug Market Size by Type (2022-2027) & (US$ Million)
Table 35. North America Neuraminidase Inhibitors Drug Market Size by Application (2016-2021) (US$ Million)
Table 36. North America Neuraminidase Inhibitors Drug Market Size by Application (2022-2027) & (US$ Million)
Table 37. North America Neuraminidase Inhibitors Drug Market Size by Country (2016-2021) & (US$ Million)
Table 38. North America Neuraminidase Inhibitors Drug Market Size by Country (2022-2027) & (US$ Million)
Table 39. Europe Neuraminidase Inhibitors Drug Market Size by Type (2016-2021) (US$ Million)
Table 40. Europe Neuraminidase Inhibitors Drug Market Size by Type (2022-2027) & (US$ Million)
Table 41. Europe Neuraminidase Inhibitors Drug Market Size by Application (2016-2021) (US$ Million)
Table 42. Europe Neuraminidase Inhibitors Drug Market Size by Application (2022-2027) & (US$ Million)
Table 43. Europe Neuraminidase Inhibitors Drug Market Size by Country (2016-2021) & (US$ Million)
Table 44. Europe Neuraminidase Inhibitors Drug Market Size by Country (2022-2027) & (US$ Million)
Table 45. Asia-Pacific Neuraminidase Inhibitors Drug Market Size by Type (2016-2021) (US$ Million)
Table 46. Asia-Pacific Neuraminidase Inhibitors Drug Market Size by Type (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Neuraminidase Inhibitors Drug Market Size by Application (2016-2021) (US$ Million)
Table 48. Asia-Pacific Neuraminidase Inhibitors Drug Market Size by Application (2022-2027) & (US$ Million)
Table 49. Asia-Pacific Neuraminidase Inhibitors Drug Market Size by Region (2016-2021) & (US$ Million)
Table 50. Asia-Pacific Neuraminidase Inhibitors Drug Market Size by Region (2022-2027) & (US$ Million)
Table 51. Latin America Neuraminidase Inhibitors Drug Market Size by Type (2016-2021) (US$ Million)
Table 52. Latin America Neuraminidase Inhibitors Drug Market Size by Type (2022-2027) & (US$ Million)
Table 53. Latin America Neuraminidase Inhibitors Drug Market Size by Application (2016-2021) (US$ Million)
Table 54. Latin America Neuraminidase Inhibitors Drug Market Size by Application (2022-2027) & (US$ Million)
Table 55. Latin America Neuraminidase Inhibitors Drug Market Size by Country (2016-2021) & (US$ Million)
Table 56. Latin America Neuraminidase Inhibitors Drug Market Size by Country (2022-2027) & (US$ Million)
Table 57. Middle East & Africa Neuraminidase Inhibitors Drug Market Size by Type (2016-2021) (US$ Million)
Table 58. Middle East & Africa Neuraminidase Inhibitors Drug Market Size by Type (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Neuraminidase Inhibitors Drug Market Size by Application (2016-2021) (US$ Million)
Table 60. Middle East & Africa Neuraminidase Inhibitors Drug Market Size by Application (2022-2027) & (US$ Million)
Table 61. Middle East & Africa Neuraminidase Inhibitors Drug Market Size by Country (2016-2021) & (US$ Million)
Table 62. Middle East & Africa Neuraminidase Inhibitors Drug Market Size by Country (2022-2027) & (US$ Million)
Table 63. Roche Company Details
Table 64. Roche Business Overview
Table 65. Roche Neuraminidase Inhibitors Drug Product
Table 66. Roche Revenue in Neuraminidase Inhibitors Drug Business (2016-2021) & (US$ Million)
Table 67. Roche Recent Development
Table 68. GSK Company Details
Table 69. GSK Business Overview
Table 70. GSK Neuraminidase Inhibitors Drug Product
Table 71. GSK Revenue in Neuraminidase Inhibitors Drug Business (2016-2021) & (US$ Million)
Table 72. GSK Recent Development
Table 73. Gilead Sciences Company Details
Table 74. Gilead Sciences Business Overview
Table 75. Gilead Sciences Neuraminidase Inhibitors Drug Product
Table 76. Gilead Sciences Revenue in Neuraminidase Inhibitors Drug Business (2016-2021) & (US$ Million)
Table 77. Gilead Sciences Recent Development
Table 78. Daiichi Sankyo Company Details
Table 79. Daiichi Sankyo Business Overview
Table 80. Daiichi Sankyo Neuraminidase Inhibitors Drug Product
Table 81. Daiichi Sankyo Revenue in Neuraminidase Inhibitors Drug Business (2016-2021) & (US$ Million)
Table 82. Daiichi Sankyo Recent Development
Table 83. Research Programs/Design for This Report
Table 84. Key Data Information from Secondary Sources
Table 85. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Neuraminidase Inhibitors Drug Market Share by Type: 2020 VS 2027
Figure 2. Oseltamivir Features
Figure 3. Zanamivir Features
Figure 4. Peramivir Features
Figure 5. Laninamivir Features
Figure 6. Global Neuraminidase Inhibitors Drug Market Share by Application: 2020 VS 2027
Figure 7. Hospital Pharmacy Case Studies
Figure 8. Retail Pharmacy Case Studies
Figure 9. Online Pharmacy Case Studies
Figure 10. Others Case Studies
Figure 11. Neuraminidase Inhibitors Drug Report Years Considered
Figure 12. Global Neuraminidase Inhibitors Drug Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 13. Global Neuraminidase Inhibitors Drug Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 14. Global Neuraminidase Inhibitors Drug Market Share by Regions: 2020 VS 2027
Figure 15. Global Neuraminidase Inhibitors Drug Market Share by Regions (2022-2027)
Figure 16. Global Neuraminidase Inhibitors Drug Market Share by Players in 2020
Figure 17. Global Top Neuraminidase Inhibitors Drug Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Neuraminidase Inhibitors Drug as of 2020
Figure 18. The Top 10 and 5 Players Market Share by Neuraminidase Inhibitors Drug Revenue in 2020
Figure 19. Global Neuraminidase Inhibitors Drug Revenue Market Share by Type (2016-2021)
Figure 20. Global Neuraminidase Inhibitors Drug Revenue Market Share by Type (2022-2027)
Figure 21. North America Neuraminidase Inhibitors Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 22. North America Neuraminidase Inhibitors Drug Market Share by Type (2016-2027)
Figure 23. North America Neuraminidase Inhibitors Drug Market Share by Application (2016-2027)
Figure 24. North America Neuraminidase Inhibitors Drug Market Share by Country (2016-2027)
Figure 25. United States Neuraminidase Inhibitors Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Canada Neuraminidase Inhibitors Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Europe Neuraminidase Inhibitors Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 28. Europe Neuraminidase Inhibitors Drug Market Share by Type (2016-2027)
Figure 29. Europe Neuraminidase Inhibitors Drug Market Share by Application (2016-2027)
Figure 30. Europe Neuraminidase Inhibitors Drug Market Share by Country (2016-2027)
Figure 31. Germany Neuraminidase Inhibitors Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. France Neuraminidase Inhibitors Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. U.K. Neuraminidase Inhibitors Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Italy Neuraminidase Inhibitors Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Russia Neuraminidase Inhibitors Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Nordic Neuraminidase Inhibitors Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Asia-Pacific Neuraminidase Inhibitors Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. Asia-Pacific Neuraminidase Inhibitors Drug Market Share by Type (2016-2027)
Figure 39. Asia-Pacific Neuraminidase Inhibitors Drug Market Share by Application (2016-2027)
Figure 40. Asia-Pacific Neuraminidase Inhibitors Drug Market Share by Region (2016-2027)
Figure 41. China Neuraminidase Inhibitors Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Japan Neuraminidase Inhibitors Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. South Korea Neuraminidase Inhibitors Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Southeast Asia Neuraminidase Inhibitors Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. India Neuraminidase Inhibitors Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Australia Neuraminidase Inhibitors Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Latin America Neuraminidase Inhibitors Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. Latin America Neuraminidase Inhibitors Drug Market Share by Type (2016-2027)
Figure 49. Latin America Neuraminidase Inhibitors Drug Market Share by Application (2016-2027)
Figure 50. Latin America Neuraminidase Inhibitors Drug Market Share by Country (2016-2027)
Figure 51. Mexico Neuraminidase Inhibitors Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Brazil Neuraminidase Inhibitors Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Middle East & Africa Neuraminidase Inhibitors Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 54. Middle East & Africa Neuraminidase Inhibitors Drug Market Share by Type (2016-2027)
Figure 55. Middle East & Africa Neuraminidase Inhibitors Drug Market Share by Application (2016-2027)
Figure 56. Middle East & Africa Neuraminidase Inhibitors Drug Market Share by Country (2016-2027)
Figure 57. Turkey Neuraminidase Inhibitors Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. Saudi Arabia Neuraminidase Inhibitors Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. UAE Neuraminidase Inhibitors Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 60. Roche Revenue Growth Rate in Neuraminidase Inhibitors Drug Business (2016-2021)
Figure 61. GSK Revenue Growth Rate in Neuraminidase Inhibitors Drug Business (2016-2021)
Figure 62. Gilead Sciences Revenue Growth Rate in Neuraminidase Inhibitors Drug Business (2016-2021)
Figure 63. Daiichi Sankyo Revenue Growth Rate in Neuraminidase Inhibitors Drug Business (2016-2021)
Figure 64. Bottom-up and Top-down Approaches for This Report
Figure 65. Data Triangulation
Figure 66. Key Executives Interviewed

以下、関連資料のご紹介

世界のスニチニブ薬市場規模・現状・予測（2021年-2027年）

Global Sunitinib Drug Market Size, Status and Forecast 2021-2027
QFJ1-6026 2021年6月 89Pages
QYResearch社発行の本調査レポートでは、スニチニブ薬の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（12.5mgカプセル、25mgカプセル、37.5mgカプセル、50mgカプセル）、用途別市場規模（腎臓がん、GIST、pNET）、主要地域別...

世界のアンブリセンタン薬市場規模・現状・予測（2021年-2027年）

Global Ambrisentan Drug Market Size, Status and Forecast 2021-2027
QFJ1-5574 2021年6月 87Pages
QYResearch社発行の本調査レポートでは、アンブリセンタン薬の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（5mg錠、10mg錠）、用途別市場規模（病院、薬局）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南...

世界のPI3キナーゼ（PI3K）阻害剤市場規模・現状・予測（2021年-2027年）

Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Size, Status and Forecast 2021-2027
QFJ1-5949 2021年6月 97Pages
QYResearch社発行の本調査レポートでは、PI3キナーゼ（PI3K）阻害剤の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（CLL-慢性リンパ性白血病、FL-濾胞性リンパ腫、その他疾患）、用途別市場規模（病院、研究所・研究機関、クリニック、その...

世界のアンジオテンシン変換酵素阻害剤市場規模・現状・予測（2021年-2027年）

Global Angiotensin Converting Enzyme Inhibitors Market Size, Status and Forecast 2021-2027
QFJ1-3807 2021年6月 96Pages
QYResearch社発行の本調査レポートでは、アンジオテンシン変換酵素阻害剤の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（ベナゼプリル（ロテンシン）、カプトプリル、エナラプリル（バソテック）、フォシノプリル、リシノプリル（プリニビル、ゼストリル...

世界の向精神薬市場規模・現状・予測（2021年-2027年）

Global Psychotropic Drug Market Size, Status and Forecast 2021-2027
QFJ1-4785 2021年6月 96Pages
QYResearch社発行の本調査レポートでは、向精神薬の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（鎮痛薬、麻酔薬、催眠薬、その他）、用途別市場規模（病院薬局、小売薬局、オンライン薬局）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、...

世界のパルボシクリブ薬市場規模・現状・予測（2021年-2027年）

Global Palbociclib Drug Market Size, Status and Forecast 2021-2027
QFJ1-5925 2021年6月 96Pages
QYResearch社発行の本調査レポートでは、パルボシクリブ薬の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（錠剤タイプパルボシクリブ薬、カプセルタイプパルボシクリブ薬）、用途別市場規模（病院、診断センター、研究所）、主要地域別市場規模（北米、ア...

世界の血管内皮増殖因子（VEGF）阻害剤市場規模・現状・予測（2021年-2027年）

Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Size, Status and Forecast 2021-2027
QFJ1-6061 2021年6月 99Pages
QYResearch社発行の本調査レポートでは、血管内皮増殖因子（VEGF）阻害剤の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（VEGF-A阻害剤、VEGF-B阻害剤、VEGF-C阻害剤、VEGF-D阻害剤）、用途別市場規模（腫瘍、眼科）、主要地...

世界の抗レトロウイルス薬市場規模・現状・予測（2021年-2027年）

Global Antiretroviral Drug Market Size, Status and Forecast 2021-2027
QFJ1-5589 2021年6月 99Pages
QYResearch社発行の本調査レポートでは、抗レトロウイルス薬の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（多剤併用、NRTI、NNRTI、プロテアーゼ阻害剤、その他）、用途別市場規模（病院、製薬会社、その他）、主要地域別市場規模（北米、アメ...

世界のアテローム性動脈硬化症薬市場規模・現状・予測（2021年-2027年）

Global Atherosclerosis Drug Market Size, Status and Forecast 2021-2027
QFJ1-3865 2021年6月 107Pages
QYResearch社発行の本調査レポートでは、アテローム性動脈硬化症薬の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（抗血小板薬、コレステロール低下薬、フィブリン酸＆オメガ-3脂肪酸誘導体、その他）、用途別市場規模（小売薬局、病院薬局、オンライン...

世界の皮膚放射線傷害治療薬市場規模・現状・予測（2021年-2027年）

Global Cutaneous Radiation Injury Drug Market Size, Status and Forecast 2021-2027
QFJ1-4082 2021年6月 100Pages
QYResearch社発行の本調査レポートでは、皮膚放射線傷害治療薬の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（経口薬、外用薬）、用途別市場規模（病院薬局、オンライン薬局、小売薬局）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国...

世界のスニチニブ薬市場規模・現状・予測（2021年-2027年） Sunitinib (marketed as Sutent by Pfizer, and previously known as SU11248) is an oral, small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor that was approved by the FDA for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST) on J…
世界のPI3キナーゼ（PI3K）阻害剤市場規模・現状・予測（2021年-2027年） PI3K inhibitors work by inhibiting PI3K enzymes, which helps in signaling the pathway for cellular functions such as growth control, metabolism, and translation initiation. There is extensive ongoing research on targeted therapies such as PI3K inhibitors with proven efficacy in oncology applications…
世界の向精神薬市場規模・現状・予測（2021年-2027年） The majority of essential psychotropic drugs are indicated to treat symptoms of mental disorders, slow down course of mental disorders, diminish disability and avoid relapse in a patient. Market Analysis and Insights: Global Psychotropic Drug Market The global Psychotropic Drug market size is projec…
世界のアンブリセンタン薬市場規模・現状・予測（2021年-2027年） Ambrisentan (U.S. trade name Letairis; E.U. trade name Volibris; India trade name Pulmonext by MSN labs) is a drug indicated for use in the treatment of pulmonary hypertension. Market Analysis and Insights: Global Ambrisentan Drug Market The global Ambrisentan Drug market size is projected to reach …
世界の抗レトロウイルス薬市場規模・現状・予測（2021年-2027年） Tire-derived fuel (TDF) is composed of shredded scrap tires. Market Analysis and Insights: Global Antiretroviral Drug Market The global Antiretroviral Drug market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027. With industry-standard…